Module 4 - Case Study 4: Vaccine PKPD, MBMA, and Beyond

This lecture by Dr. S.Y. Amy Cheung, a senior director of Integrated Drug Development at Certara, aligns the challenges of vaccine development, especially with the rapid progression of the COVID-19 pandemic. She highlights the usefulness of MIDD in vaccine development by demonstrating the importance of knowledge building through model interconnectedness of a compound to support vaccine drug development.
This module is part of the educational series “Model-Informed Drug Development (MIDD): Methods Advancing Medical Products to Patients”. The educational content was developed for regulatory scientists by experts in the field in partnership with the Critical Path Institute and funded by FDA CDER Office of Translational Sciences. As part of Multidisciplinary Education and Exchange initiatives, CDER’s Quantitative Medicine Center of Excellence is making this resource accessible to all, supporting community-wide educational enrichment.
Disclaimer: The presentations in this educational series reflect the views of the presenters and should not be construed to represent FDA’s views or policies.